Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01114581 · ClinicalTrials.gov registry record · Phase 2
Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection
A Phase 2 study, sponsored by Reckitt Benckiser.
- Completed
- Registry status
- Phase 2
- Development phase
- 38
- Enrollment target
NCT01114581 is a Phase 2 study that has completed, run by Reckitt Benckiser. The registered enrollment target is 38 participants.
The verdict
NCT01114581, a Phase 2 study, has completed, sponsored by Reckitt Benckiser.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 38 participants
- Enrollment target
Study Summary
The purpose of this research study is to explore the mechanism of action of Mucinex, an oral, over-the-counter, FDA approved expectorant in patients with acute respiratory tract infections.
Interventions
- DRUG Placebo
- DRUG Mucinex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01114581
The ClinicalTrials.gov registry entry for NCT01114581 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Reckitt Benckiser, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01114581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01114581 about?
NCT01114581 is a clinical study titled "Evaluating the Effect of Mucinex 1200mg on Mucociliary and Cough Clearance During an Acute Respiratory Infection". The purpose of this research study is to explore the mechanism of action of Mucinex, an oral, over-the-counter, FDA approved expectorant in patients with acute respiratory tract infections.
What is the current status of trial NCT01114581?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 38 participants. The study started on 2010-04. Estimated completion is 2011-04.
What interventions are being tested in trial NCT01114581?
The interventions under investigation include: Placebo (DRUG), Mucinex (DRUG).
Who is sponsoring clinical trial NCT01114581?
This trial is sponsored by Reckitt Benckiser, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.